Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours

The FDA-approved starting dosage of capecitabine is 1,250 mg/m(2), and market research indicates that U.S. physicians routinely prescribe 1,000 mg/m(2). Retrospective analyses however report reduced toxicity and efficacy in a subset of patients with the 3R/3R genotype of the thymidylate synthase gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Soo, Ross Andrew, Syn, Nicholas, Lee, Soo-Chin, Wang, Lingzhi, Lim, Xn-Yii, Loh, Marie, Tan, Sing-Huang, Zee, Ying-Kiat, Wong, Andrea Li-Ann, Chuah, Benjamin, Chan, Daniel, Lim, Siew-Eng, Goh, Boon-Cher, Soong, Richie, Yong, Wei-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906519/
https://www.ncbi.nlm.nih.gov/pubmed/27296624
http://dx.doi.org/10.1038/srep27826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906519/
https://www.ncbi.nlm.nih.gov/pubmed/27296624
http://dx.doi.org/10.1038/srep27826

Ejemplares similares